News | November 16, 2023
Sanofi completes closing for potential first-in-class vaccine against ExPEC
Extraintestinal pathogenic E. coli (ExPEC) has been identified as the leading bacterial cause of sepsis
Extraintestinal pathogenic E. coli (ExPEC) has been identified as the leading bacterial cause of sepsis
Approval based on results from TOPAZ-1 global Phase III trial and a Chinese patient
Reports revenue growth of 9% to INR 882 crores in Q2 FY24
Expanded collaboration with Vanguard Renewables aims to significantly increase the productivity of US renewable natural gas generation
The company has raised US$4.5 million in funding for its AI operating system
Sales in the US region grew well, partially offset by the decline in the LATAM and European regions
US business grew by +12.8% YoY
Q2FY24 EBITDA up by 105% y-o-y at Rs. 28 crore
Rocuronium Bromide Injection had estimated annual sales of USD 54 million in the US (IQVIA MAT August 2023).
We are redesigning Bayer to focus only on what’s essential for our mission, ‘Health for all, hunger for none’”
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
